BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29970031)

  • 21. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
    Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
    Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.
    Mitani Y; Oue N; Hamai Y; Aung PP; Matsumura S; Nakayama H; Kamata N; Yasui W
    J Pathol; 2005 Jan; 205(1):65-73. PubMed ID: 15586362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards sustained silencing of HER2/neu in cancer by epigenetic editing.
    Falahi F; Huisman C; Kazemier HG; van der Vlies P; Kok K; Hospers GA; Rots MG
    Mol Cancer Res; 2013 Sep; 11(9):1029-39. PubMed ID: 23814024
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 induces distinct epigenetic states at its direct target promoters.
    Vrba L; Junk DJ; Novak P; Futscher BW
    BMC Genomics; 2008 Oct; 9():486. PubMed ID: 18922183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of beta-catenin-mediated TCF-signalling in prostate cancer cell lines by wild-type and mutant p53.
    Prowald A; Cronauer MV; von Klot C; Eilers T; Rinnab L; Herrmann T; Spindler KD; Montenarh M; Jonas U; Burchardt M
    Prostate; 2007 Dec; 67(16):1751-60. PubMed ID: 17929268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance.
    Sankala H; Vaughan C; Wang J; Deb S; Graves PR
    Arch Biochem Biophys; 2011 Aug; 512(1):52-60. PubMed ID: 21621504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Various p53 mutant proteins differently regulate the Ras circuit to induce a cancer-related gene signature.
    Solomon H; Buganim Y; Kogan-Sakin I; Pomeraniec L; Assia Y; Madar S; Goldstein I; Brosh R; Kalo E; Beatus T; Goldfinger N; Rotter V
    J Cell Sci; 2012 Jul; 125(Pt 13):3144-52. PubMed ID: 22427690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
    Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
    Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis.
    Yallowitz AR; Li D; Lobko A; Mott D; Nemajerova A; Marchenko N
    Mol Cancer Res; 2015 Apr; 13(4):743-54. PubMed ID: 25573952
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes.
    Redman-Rivera LN; Shaver TM; Jin H; Marshall CB; Schafer JM; Sheng Q; Hongo RA; Beckermann KE; Wheeler FC; Lehmann BD; Pietenpol JA
    Nat Commun; 2021 Aug; 12(1):5184. PubMed ID: 34465782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.
    Mehta SA; Christopherson KW; Bhat-Nakshatri P; Goulet RJ; Broxmeyer HE; Kopelovich L; Nakshatri H
    Oncogene; 2007 May; 26(23):3329-37. PubMed ID: 17130833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.
    Shetzer Y; Molchadsky A; Rotter V
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27235476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diverse and cancer type‑specific roles of the p53 R248Q gain‑of‑function mutation in cancer migration and invasiveness.
    Olszewski MB; Pruszko M; Snaar-Jagalska E; Zylicz A; Zylicz M
    Int J Oncol; 2019 Apr; 54(4):1168-1182. PubMed ID: 30968154
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gain of oncogenic function of p53 mutants regulates E-cadherin expression uncoupled from cell invasion in colon cancer cells.
    Roger L; Jullien L; Gire V; Roux P
    J Cell Sci; 2010 Apr; 123(Pt 8):1295-305. PubMed ID: 20332115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRD7 is a candidate tumour suppressor gene required for p53 function.
    Drost J; Mantovani F; Tocco F; Elkon R; Comel A; Holstege H; Kerkhoven R; Jonkers J; Voorhoeve PM; Agami R; Del Sal G
    Nat Cell Biol; 2010 Apr; 12(4):380-9. PubMed ID: 20228809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities.
    Kollareddy M; Dimitrova E; Vallabhaneni KC; Chan A; Le T; Chauhan KM; Carrero ZI; Ramakrishnan G; Watabe K; Haupt Y; Haupt S; Pochampally R; Boss GR; Romero DG; Radu CG; Martinez LA
    Nat Commun; 2015 Jun; 6():7389. PubMed ID: 26067754
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
    Viotti J; Duplan E; Caillava C; Condat J; Goiran T; Giordano C; Marie Y; Idbaih A; Delattre JY; Honnorat J; Checler F; Alves da Costa C
    Oncogene; 2014 Apr; 33(14):1764-75. PubMed ID: 23644658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells.
    Wang ZT; Chen ZJ; Jiang GM; Wu YM; Liu T; Yi YM; Zeng J; Du J; Wang HS
    Cell Signal; 2016 May; 28(5):506-515. PubMed ID: 26876786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis.
    Weinmann L; Wischhusen J; Demma MJ; Naumann U; Roth P; Dasmahapatra B; Weller M
    Cell Death Differ; 2008 Apr; 15(4):718-29. PubMed ID: 18202704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.